RNAi Therapeutics and Technology Market

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of the RNAi therapeutics market and its likely evolution in the short-mid term to long term.

Chapter 3 provides a general overview of RNAi therapeutics, including a discussion on the historical background. In addition, it includes information on the type of RNA molecule, along with information on their mechanisms of action and application areas. Further, it highlights the key advantages and challenges associated with this domain.

Chapter 4 includes information on over 200 RNAi pipeline candidates that are currently in different stages of development. It features a detailed analysis of the pipeline molecules, based on several relevant parameters, such as phase of development, target indication(s), key therapeutic areas, type of RNAi molecule, target genes, route of administration and special drug designation (if any). 

Chapter 5 presents the detailed overview of players engaged in the development of RNAi therapeutics, along with information on their year of establishment, company size and location of headquarters. In addition, it features a logo landscape of product developers based on location of headquarters and company size.

Chapter 6 presents a three-dimensional bubble analysis of key players engaged in this domain, evaluating their developer strength (on the basis of employee count and years of experience) and product portfolio strength (on the basis of number of RNAi molecules across different phases of development, type of RNAi molecule offered, purpose of technology and target therapeutic areas).

Chapter 7 contains detailed profiles of drug candidates that are in the advanced stages of development (phase II/III and above). Each drug profile features information on the current development status of the drug, along with details on its developer, mechanism of action, route of administration, affiliated technology platform (if available), dosage and recent clinical trial results

Chapter 8 provides an analysis of the current market landscape of technology platforms available for the development of RNAi therapeutics, based on several relevant parameters such as, purpose of technology, type of molecule (s) delivered and type of cell (s) / tissue (s) targeted. In addition, the chapter includes an analysis on technology developer(s), highlighting their year of their establishment, company size and location of headquarters. The chapter also includes brief profiles of key RNAi-based drug discovery / development technology platforms and drug delivery technologies (shortlisted on the basis of competitiveness score). Each profile features details on the various pipeline molecules that have been / are being developed using the technology and insights from patents associated with the technology.

Chapter 9 presents the technology competitiveness analysis, benchmarking RNAi technologies, based on supplier power (in terms of in terms of company size and years of experience) and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 10 highlights the potential target indications (segregated by various therapeutic areas, including oncological disorders, infectious diseases, metabolic disorders, ophthalmic diseases and genetic disorders) that are currently the prime focus of companies engaged in the development of RNAi therapeutics.

Chapter 11 is an analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, current status, phase of development, type of RNAi molecule, enrolled patient population and regional distribution of trials.

Chapter 12 presents an analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) in this field.

Chapter 13 provides insights from a detailed patent analysis, presenting an overview of the filed / granted patents related to RNAi therapeutics since 2016, based on type of patent (granted patents, patent applications and others), publication year, regional applicability, CPC symbols, emerging focus areas and the leading industry / academic players (in terms of the number of patents filed / granted), and patent valuation. The chapter also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 14 provides a detailed review of around 3,000 peer-reviewed, scientific articles related to research on RNAi therapeutics, based on several relevant parameters, such as year of publication, type of publication, popular keywords, top journals, top publishers, key copyright holders and key funding institutes.

Chapter 15 features an elaborate analysis the various partnerships related to RNAi therapeutics inked by players engaged in this domain, based on various parameters, such as the type of partnership, year of partnership, target disease indication, therapeutic area, type of RNAi molecule, financial details (wherever applicable), focus area of collaboration and most active players (in terms of number of partnerships).

Chapter 16 presents details on various investments various investments made by players engaged in this domain, during the period 2016-2021, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings), amount invested, type of RNAi molecule, most active players (in terms of number and amount of funding instances) and key investors (in terms of number of instances).

Chapter 17 highlights various commercialization strategies that can be adopted by drug developers engaged in this domain, across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing of the drug. The aspects covered in the chapter include details provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 18 discusses the use of miRNAs as potential biomarkers and enlists several miRNA biomarkers currently under investigation. In addition, the chapter provides the pipeline of diagnostic kits that have already been approved or are under development.

Chapter 19 provides information on the companies that are actively supporting the development of RNAi therapeutics market. These include contract manufacturers, contract researcher organizations and other service providers. In addition, the chapter includes an analysis based on parameters such as type of service provider, location of their headquarters and type of RNA molecule. 

Chapter 20 provides an informed estimate of the annual clinical and commercial demand for RNAi therapeutics, taking into account the target patient population in ongoing and planned clinical trials of RNAi therapeutics, sponsored by both industry and non-industry players.

Chapter 21 presents an informed forecast analysis, highlighting the future potential of the market, till the year 2035. It also includes future sales projections of RNAi therapeutics that are either marketed or in advanced stages of clinical development (phase II/III and above). Sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition from other drug classes and the likely price of products. The chapter also presents a detailed market segmentation on the basis of [A] key therapeutic areas (oncological disorders, genetic disorders, metabolic disorders, hematological disorders, ophthalmic disorders and other disorders), [B] route of administration (subcutaneous, intravenous, topical and intradermal), [C] share of leading industry players, [D] type of RNAi molecule (siRNA and shRNA) and [E] key geographical regions (North America, Europe and Asia-Pacific).

Chapter 22 provides a detailed discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the RNAi therapeutics market.

Chapter 23 summarizes the entire report. It presents the list of key takeaways and offers our independent opinion on the current market scenario.

Chapter 24 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market.

Chapter 25 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 26 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report 
1.2. Research Methodology
1.3. Market Segmentations
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Key Milestones and Historical Trends
3.2.1. Discovery of RNAi
3.2.2. RNAi Therapy Development Efforts

3.3. Mechanism of RNAi
3.3.1. Components of RNAi
3.3.2. Cellular Mechanism

3.4. Types of RNAi Molecules
3.4.1. siRNA
3.4.2. miRNA
3.4.3. shRNA

3.5. Applications of RNAi
3.5.1 Functional Genomics
3.5.2 Therapeutics
3.5.3. Biotechnology
3.5.4. Genome-scale Screening

3.6. Advantages and Disadvantages of RNAi
3.6.1 Advantages of RNAi
3.6.2 Disadvantages of RNAi
3.6.3 Case Study: Concerns Discussed During Regulatory Submissions in Clinic

3.7. Future Perspectives

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. RNAi Therapeutics: Marketed and Development Pipeline
4.2.1. Analysis by Type of RNAi Molecule
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Type of Molecule and Phase of Development
4.2.4. Analysis by Target Gene
4.2.5. Analysis by Therapeutic Area
4.2.6. Analysis by Route of Administration
4.2.7. RNAi Therapeutics: Special Designations
4.2.8. Key Players

5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. RNAi Therapeutics: Developer Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Location of Headquarters (Country-wise)
5.2.5. Key Players: Analysis by Number of Drug Candidates

5.3 RNAi Therapeutics: Regional Landscape

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions / Key Parameters
6.3. Methodology
6.4. Company Competitive Analysis: RNAi Therapeutics Developers
6.4. Developers based in North America
6.5. Developers based in Europe
6.6. Developers based in Asia-Pacific

7. APPROVED AND LATE STAGE RNAi THERAPEUTICS
7.1. Chapter Overview
7.2. Onpattro®
7.2.1. Drug Overview
7.2.2. Technology Overview
7.2.3. Current Development Status
7.2.4. Recent Clinical Trial Results
7.2.5. Recent Partnerships

7.3. Givlaari®
7.3.1. Drug Overview
7.3.2. Technology Overview
7.3.3. Current Development Status
7.3.4. Recent Clinical Trial Results
7.3.5. Recent Partnerships

7.4. Leqvio®
7.4.1. Drug Overview
7.4.2. Technology Overview
7.4.3. Current Development Status
7.4.4. Recent Clinical Trial Results
7.4.5. Recent Partnerships

7.5. Oxlumo™
7.5.1. Drug Overview
7.5.2. Technology Overview
7.5.3. Current Development Status
7.5.4. Recent Clinical Trial Results
7.5.5. Recent Partnerships

7.6. Fitusiran
7.6.1. Drug Overview
7.6.2. Technology Overview
7.6.3. Current Development Status
7.6.4. Recent Clinical Trial Results

7.7. Vutrisiran
7.7.1. Drug Overview
7.7.2. Technology Overview
7.7.3. Current Development Status
6.7.4. Recent Clinical Trial Results

7.8. SYL 1001
7.8.1. Drug Overview
7.8.2. Technology Overview
7.8.3. Current Development Status
7.8.4. Recent Clinical Trial Results

7.9. Vigil-EWS
7.9.1. Drug Overview
7.9.2. Technology Overview
7.9.3. Current Development Status
7.9.4. Recent Clinical Trial Results

7.10. SR-061
7.10.1. Drug Overview
7.10.2. Technology Overview
7.10.3. Current Development Status

7.11. Nedosiran
7.11.1. Drug Overview
7.11.2. Technology Overview
7.11.3. Current Development Status
7.11.4. Recent Clinical Trial Results

8. TECHNOLOGY PLATFORMS AND DELIVERY SYSTEMS
8.1. Chapter Overview
8.2. Components of RNAi Delivery Systems
8.2.1. RNAi Triggers
8.2.1.1. Asymmetric siRNA (cp-siRNA)
8.2.1.2. DNA Directed RNAi (ddRNAi)
8.2.1.3. Dicer Substrate siRNA (DsiRNA)
8.2.1.4. Naked siRNA
8.2.1.5. Self-Deliverable RNA (sd-RNA)
8.2.1.6. Self-Deliverable rxRNA (sd-rxRNA)
8.2.1.7. Unlocked Nucleobase Analog (UNA) Containing siRNA (UsiRNA)

8.2.2. Technology Platforms and Delivery Systems
8.2.2.1. Analysis by Purpose of Technology
8.2.2.2. Analysis by Type of Molecule (s) Delivered
8.2.2.3. Analysis by Type of Cell (s) / Tissue (s) Targeted

8.2.3. Technology Platforms: List of Developers
8.2.3.1. Analysis by Year of Establishment
8.2.3.2. Analysis by Company Size
8.2.3.3. Analysis by Location of Headquarters (Continent-wise)
8.2.3.4. Analysis by Location of Headquarters (Country-wise)

8.2.4. Technology Platform: Profiles
8.2.4.1. Conjugated Delivery Technologies
8.2.4.1.1. GalNAc Conjugate Delivery System, Alnylam Pharmaceuticals
8.2.4.1.1.1. Technology Overview
8.2.4.1.1.2 Pipeline Molecules in Development
8.2.4.1.1.3 Analyst’s Perspective

8.2.4.1.2. Protein Nanoparticle (PNP) Delivery Technology, Ariz Precision Medicine
8.2.4.1.2.1. Technology Overview
8.2.4.1.2.2. Pipeline Molecules in Development
8.2.4.1.2.3 Analyst’s Perspective

8.2.4.2.3 Targeted RNAi Molecule (TRiM) Platform, Arrowhead Pharmaceuticals
8.2.4.2.3.1. Technology Overview
8.2.4.2.3.2 Pipeline Molecules in Development
8.2.4.2.3.3 Analyst’s Perspective

8.2.4.2. Drug Discovery and Development Technologies
8.2.4.2.1. GalXC Conjugated RNAi Technology Platform, Dicerna Pharmaceuticals
8.2.4.2.1.1. Technology Overview
8.2.4.2.1.2 Pipeline Molecules in Development
8.2.4.2.1.3 Analyst’s Perspective

8.2.4.2.2. The Vigil Platform, Gradalis
8.2.4.2.2.1. Technology Overview
8.2.4.2.2.2 Pipeline Molecules in Development
8.2.4.2.2.3 Analyst’s Perspective

8.2.4.2.3. mRNAi GOLD Platform, Silence Therapeutics
8.2.4.2.3.1. Technology Overview
8.2.4.2.3.2 Pipeline Molecules in Development
8.2.4.2.3.3 Analyst’s Perspective

9. TECHNOLOGY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions / Key Parameters
9.3. Methodology
9.4. Technology Competitiveness Analysis: RNAi Therapeutics Technologies
9.4.1. Technology Competitiveness Analysis: Drug Delivery Technologies
9.4.2. Technology Competitiveness Analysis: Drug Discovery / Development Technologies

10. KEY THERAPEUTIC INDICATIONS
10.1. Chapter Overview
10.2. Oncological Disorders
10.2.1. Analysis by Target Indication and Phase of Development
10.2.2. Analysis by Type of RNAi Molecule

10.3. Infectious Diseases
10.3.1. Analysis by Target Indication and Phase of Development
10.3.2. Analysis by Type of RNAi Molecule

10.4. Metabolic Disorders
10.4.1. Analysis by Target Indication and Phase of Development
10.4.2. Analysis by Type of RNAi Molecule

10.5. Ophthalmic Diseases
10.5.1. Analysis by Target Indication and Phase of Development
10.5.2. Analysis by Type of RNAi Molecule

10.6. Genetic Disorders
10.6.1. Analysis by Target Indication and Phase of Development
10.6.2. Analysis by Type of RNAi Molecule

11. CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. RNAi Therapeutics: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Trial Phase
11.3.3. Analysis by Trial Recruitment Status
11.3.4. Analysis by Type of Sponsor / Collaborator
11.3.5. Analysis by Type of RNAi Molecule and Trial Recruitment Status
11.3.6. Analysis by Therapeutic Area
11.3.7. Geographical Analysis by Number of Clinical Trials
11.3.8. Geographical Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
11.3.9. Geographical Analysis by Number of Clinical Trials and Type of RNAi Molecule
11.3.10. Geographical Analysis by Number of Clinical Trials, Type of RNAi Molecule and Trial Phase
11.3.11. Geographical Analysis by Number of Clinical Trials and Therapeutic Area
11.3.12. Geographical Analysis by Number of Clinical Trials, Therapeutic Area and Trial Phase
11.3.13. Geographical Analysis of Enrolled Patient Population by Location of Trial
11.3.14. Geographical Analysis of Enrolled Patient Population by Trial Phase and Trial Recruitment Status
11.3.15. Geographical Analysis of Enrolled Patient Population by Type of RNAi Molecule and Location of Trial
11.3.16. Geographical Analysis of Enrolled Patient Population by Type of RNAi Molecule, Trial Phase and Location of Trial
11.3.17. Geographical Analysis of Enrolled Patient Population by Therapeutic Area and Location of Trial
11.3.18. Geographical Analysis of Enrolled Patient Population by Therapeutic Area. Trial Phase and Location of Trial

11.4. Concluding Remarks
11.4.1. Key Therapeutic Candidates
11.4.2. Key Clinical Trials

12. KEY OPINION LEADERS
12.1. Chapter Overview
12.2. RNAi Therapeutics: Key Opinion Leaders
12.2.1. Analysis by Type of Organization
12.2.2. Analysis by Qualification
12.2.3. Analysis by Geographical Location of KOLs
12.2.4. Most Prominent Organizations: Analysis by Number of KOLs
12.2.5. KOL Activeness v/s KOL Strength
12.2.6. Most Prominent KOLs: Analysis by KOL Strength
12.2.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

13. PATENT ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. RNAi Therapeutics: Patent Analysis
13.3.1. Analysis by Publication Year
13.3.2. Analysis by Patent Type and Publication Year
13.3.3. Analysis by CPC Code
13.3.4. Analysis by Type of Applicant
13.3.5. Analysis by Geography
13.3.5.1. Analysis by Geography: North American Scenario
13.3.5.2. Analysis by Geography: European Scenario
13.3.5.3. Analysis by Geography: Asia-Pacific Scenario
13.3.6. Emerging Focus Areas
13.3.7. Leading Players: Analysis by Number of Patents

13.4. RNAi Therapeutics: Patent Benchmarking Analysis
13.4.1. Analysis by Key Patent Characteristics
13.4.1.1. Arrowhead Pharmaceuticals and Sirna Therapeutics
13.4.1.2. Other Leading Patent Assignees
13.5. RNAi Therapeutics: Patent Valuation Analysis

14. PUBLICATION ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Analysis by Year of Publication
14.4. Analysis by Type of Publication
14.5. Most Popular Keywords
14.6. Most Popular Journals: Analysis by Number of Publications
14.7. Most Popular Publisher: Analysis by Number of Publications
14.8. Most Popular Copyright Holders: Analysis by Number of Publications
14.9. Key Funding Institutes: Analysis by Number of Publications

15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models

15.3. RNAi Therapeutics: Recent Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Type of RNAi Molecule
15.3.4. Analysis by Scale of Partnership
15.3.5. Analysis by Therapeutic Area
15.3.6. Most Active Players: Analysis by Number of Partnerships
15.3.7. Regional Analysis
15.3.7.1. Country-wise Distribution
15.3.7.2. Intercontinental and Intracontinental Deals

16. FUNDING AND INVESTMENT ANALYSIS
16.1. Chapter Overview
16.2. Types of Funding
16.3. RNAi Therapeutics: Funding and Investment Analysis
16.3.1. Analysis by Cumulative Funding Instances, 2014-2021
16.3.2. Analysis by Amount Invested
16.3.3. Analysis by Type of Funding
16.3.4. Analysis by Year and Type of Funding
16.3.5. Analysis of Amount Invested Across Different Types of RNAi Molecules
16.3.6. Regional Analysis by Amount Invested
16.3.7. Most Active Players
16.3.8. Key Investors
16.4. Concluding Remarks

17. KEY COMMERCIALIZATION STRATEGIES
17.1. Chapter Overview
17.2. Successful Drug Launch Strategy: ROOTS Framework
17.3. Successful Drug Launch Strategy: Product Differentiation
17.4. Commonly Adopted Commercialization Strategies based on Stage of Development of the Product
17.5. Approved RNAi Therapeutics

17.6. Key Commercialization Strategies Adopted by RNAi-based Therapy Developers
17.6.1. Strategies Adopted Before Therapy Approval
17.6.1.1. Participation in Global Events
17.6.1.1.1. Onpattro
17.6.1.1.2. Givlaari
17.6.1.1.3. Oxlumo
17.6.1.2. Collaboration with Stakeholders and Pharmaceutical Firms
17.6.1.2.1. Leqvio
17.6.1.3. Indication Expansion
17.6.1.3.1. Onpattro
17.6.1.3.2. Givlaari
17.6.1.3.3. Oxlumo
17.6.1.3.4. Leqvio

17.6.2. Strategies Adopted During / Post Therapy Approval
17.6.2.1. Participation in Global Events
17.6.2.1.1. Onpattro
17.6.2.1.2. Leqvio
17.6.2.2. Geographical Expansion
17.6.2.2.1. Onpattro
17.6.2.2.2. Givlaari
17.6.2.2.3. Oxlumo
17.6.2.2.4. Leqvio

17.6.2.3. Patient Assistance Programs
17.6.2.3.1. Onpattro
17.6.2.3.2. Givlaari
17.6.2.3.3. Oxlumo

17.6.2.4. Awareness Through Product Websites
17.6.2.5. Collaboration with Stakeholders and Pharmaceutical Firms
17.6.2.5.1. Onpattro
17.6.2.5.2. Givlaari
17.6.2.5.3. Oxlumo
17.6.2.5.4. Leqvio

17.6.2.6. Aligning with Government Initiatives to Ensure High Adoption Rate
17.6.2.6.1. Onpattro
17.6.2.6.2. Givlaari
17.6.2.6.3. Leqvio

17.7. Concluding Remarks

18. RNAi IN DIAGNOSTICS
18.1. Chapter Overview
18.2. Key Characteristics of Biomarkers
18.3. Circulating miRNA Biomarkers

18.4. miRNA Biomarkers in Oncological Disorders
18.4.1. Importance of Early Cancer Detection
18.4.2. Cancer Screening and Diagnosis
18.4.3. Conventional Cancer Diagnostics
18.4.3.1. Biopsy
18.4.4. Need for Non-Invasive Approaches

18.4.5. Key Indications
18.4.5.1. Breast Cancer
18.4.5.2. Colorectal Cancer
18.4.5.3. Gastric Cancer
18.4.5.4. Hematological Cancer
18.4.5.4.1. Acute Myeloid Leukemia
18.4.5.4.2 Lymphoma
18.4.5.5. Lung Cancer
18.4.5.6. Prostate Cancer

18.5. miRNA Biomarkers in Cardiovascular Diseases
18.5.1. Key Indications
18.5.1.1. Coronary Artery Disease
18.5.1.2. Myocardial Infarction

18.6. miRNA Based Diagnostic Tests

19. RNAi THERAPEUTICS SERVICE PROVIDERS
19.1. Chapter Overview
19.2. Analysis by Types of Service Providers
19.3. RNAi Therapeutics: List of CROs
19.3.1. Analysis by Year of Establishment
19.3.2. Analysis by Location of Headquarters
19.3.3. Analysis by Company Size
19.3.4. Analysis by Type of RNAi Molecule

19.4. RNAi Therapeutics: List of CMOs
19.4.1. Analysis by Year of Establishment
19.4.2. Analysis by Location of Headquarters
19.4.3. Analysis by Company Size
19.4.4. Analysis by Type of RNAi Molecule

19.5. RNAi Therapeutics: List of Consumables and Other Service Providers
19.5.1. Analysis by Year of Establishment
19.5.2. Analysis by Location of Headquarters
19.5.3. Analysis by Company Size
19.5.4. Analysis by Type of RNAi Molecule

20. DEMAND ANALYSIS
20.1. Chapter Overview
20.2. Methodology
20.3. Global Demand for RNAi Therapeutics, 2022-2035
20.3.1. Analysis by Therapeutic Approach
20.3.2. Analysis by Target Therapeutic Area
20.3.3. Analysis by Route of Administration
20.3.4. Analysis by Key Players
20.3.5. Analysis by Geography

21. MARKET SIZING AND OPPORTUNITY ANALYSIS
21.1. Chapter Overview
21.2. Scope and Limitations
21.3. Key Assumptions and Forecast Methodology
21.4. Overall RNAi Therapeutics Market, 2022-2035
21.4.1. RNAi Therapeutics Market: Analysis by Type of RNAi Molecule
21.4.2. RNAi Therapeutics Market: Analysis by Therapeutic Area
21.4.3. RNAi Therapeutics Market: Analysis by Route of Administration
21.4.4. RNAi Therapeutics Market: Share of Leading Players
21.4.5. RNAi Therapeutics Market: Analysis by Geography

21.5. RNAi Therapeutics Market: Value Creation Analysis
21.6. RNAi Therapeutics Market: Product-wise Sales Forecasts
21.6.1. Onpattro®
21.6.1.1. Target Patient Population
21.6.1.2. Sales Forecast
21.6.1.3. Net Present Value
21.6.1.4. Value Creation Analysis

21.6.2. Givlaari™
21.6.2.1. Target Patient Population
21.6.2.2. Sales Forecast
21.6.2.3. Net Present Value
21.6.2.4. Value Creation Analysis

21.6.3. Leqvio®
21.6.3.1. Target Patient Population
21.6.3.2. Sales Forecast
21.6.3.3. Net Present Value
21.6.3.4. Value Creation Analysis

21.6.4. Oxlumo™
21.6.4.1. Target Patient Population
21.6.4.2. Sales Forecast
21.6.4.3. Net Present Value
21.6.4.4. Value Creation Analysis

21.6.5. Fitusiran
21.6.5.1. Target Patient Population
21.6.5.2. Sales Forecast
21.6.5.3. Net Present Value
21.6.5.4. Value Creation Analysis

21.6.6. Vutrisiran
21.6.6.1. Target Patient Population
21.6.6.2. Sales Forecast
21.6.6.3. Net Present Value
21.6.6.4. Value Creation Analysis

21.6.7. SYL-1001
21.6.7.1. Target Patient Population
21.6.7.2. Sales Forecast
21.6.7.3. Net Present Value
21.6.7.4. Value Creation Analysis

21.6.8. Vigil-EWS
21.6.8.1. Target Patient Population
21.6.8.2. Sales Forecast
21.6.8.3. Net Present Value
21.6.8.4. Value Creation Analysis

21.6.9. Nedosiran
21.6.9.1. Target Patient Population
21.6.9.2. Sales Forecast
21.6.9.3. Net Present Value
21.6.9.4. Value Creation Analysis

22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats
22.6 Comparison of SWOT Factors
22.6.1 Concluding Remarks

23. INTERVIEW TRANSCRIPT(S)

24. CONCLUSION
24.1. Chapter Overview
24.2. Key Takeaways

25. APPENDIX 1: TABULATED DATA

26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Competitive Landscape
Figure 2.3 Executive Summary: Technology Platforms and Delivery Systems
Figure 2.4 Executive Summary: Clinical Trial Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Publication Analysis
Figure 2.7 Executive Summary: Partnerships and Collaborations
Figure 2.8 Executive Summary: Funding and Investment Analysis
Figure 2.9 Executive Summary: Demand Analysis
Figure 2.10 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1 RNA Interference: Key Milestones and Historical Evolution
Figure 3.2 RNA Interference: Key Components
Figure 3.3 RNA Interference: Working Mechanism
Figure 3.4 RNA Interference: Types of Delivery Systems
Figure 3.6 RNA Interference: Advantages and Disadvantages
Figure 4.1 RNAi Therapeutics: Distribution by Type of RNAi Molecule
Figure 4.2 RNAi Therapeutics: Distribution by Phase of Development
Figure 4.3 RNAi Therapeutics: Distribution by Molecule and Phase of Development
Figure 4.4 RNAi Therapeutics Pipeline: Distribution by Target Gene
Figure 4.5 RNAi Therapeutics Pipeline: Distribution by Therapeutic Area
Figure 4.6 RNAi Therapeutics Pipeline: Distribution by Route of Administration
Figure 4.7 RNAi Therapeutics: Distribution by Special Drug Designation
Figure 4.8 RNAi Therapeutics: Distribution by Special Drug Designation and Therapeutic Area
Figure 4.9 RNAi Therapeutics: Key Players
Figure 5.1 RNAi Therapeutics Developers: Distribution by Year of Establishment
Figure 5.2 RNAi Therapeutics Developers: Distribution by Company Size
Figure 5.3 RNAi Therapeutics Developers: Distribution by Location of Headquarters
Figure 5.4 RNAi Therapeutics Developers: Distribution by Location of Headquarters (Country-wise)
Figure 5.5 RNAi Therapeutics Developers: Key Players
Figure 6.6 RNAi Therapeutics Developers: Regional Landscape
Figure 6.1 Company Competitiveness Analysis: Developers based in North America
Figure 6.2 Company Competitiveness Analysis: Developers based in Europe
Figure 6.3 Company Competitiveness Analysis: Developers based in Asia-Pacific
Figure 7.1 Onpattro (Alnylam Pharmaceuticals): Timeline of Regulatory Approvals Across Regions
Figure 7.2 Lipid Nanoparticles Delivery System: Mode of Action
Figure 7.3 Givlaari (Alnylam Pharmaceuticals): Timeline of Regulatory Approvals Across Regions
Figure 7.4 ESC-GalNAc Delivery System: Mode of Action
Figure 7.5 Leqvio (Alnylam Pharmaceuticals): Timeline of Regulatory Approvals Across Regions
Figure 8.1 RNAi Technology Platforms: Distribution by Purpose of Technology
Figure 8.2 RNAi Technology Platforms: Distribution by Type of Molecule(s) Delivered
Figure 8.3 RNAi Technology Platforms: Distribution by Type of Cell (s) / Tissue (s) Targeted
Figure 8.4 RNAi Technology Developers: Distribution by Year of Establishment
Figure 8.5 RNAi Technology Developers: Distribution by Company Size
Figure 8.6 RNAi Technology Developers: Distribution by Location of Headquarters (Continent-wise)
Figure 8.7 RNAi Technology Developers: Distribution by Location of Headquarters (Country-wise)
Figure 8.8 Protein Nanoparticle Delivery System: Technology Components and Its Assembly
Figure 8.9 mRNAi GOLD Platform: Advantages
Figure 9.1 Technology Competitiveness Analysis: Drug Delivery Technologies
Figure 9.2 Technology Competitiveness Analysis: Drug Discovery / Development Technologies
Figure 10.1 RNAi Therapeutics for Oncological Disorders: Distribution by Target Indication and Phase of Development
Figure 10.2 RNAi Therapeutics for Oncological Disorders: Distribution by Type of RNAi Molecule
Figure 10.3 RNAi Therapeutics for Infectious Diseases: Distribution by Target Indication and Phase of Development
Figure 10.4 RNAi Therapeutics for Infectious Diseases: Distribution by Type of RNAi Molecule
Figure 10.5 RNAi Therapeutics for Metabolic Disorders: Distribution by Target Indication and Phase of Development
Figure 10.6 RNAi Therapeutics for Metabolic Disorders: Distribution by Type of RNAi Molecule
Figure 10.7 RNAi Therapeutics for Ophthalmic Diseases: Distribution by Target Indication and Phase of Development
Figure 10.8 RNAi Therapeutics for Ophthalmic Diseases: Distribution by Type of RNAi Molecule
Figure 10.9 RNAi Therapeutics for Genetic Disorders: Distribution by Target Indication and Phase of Development
Figure 10.10 RNAi Therapeutics for Genetic Disorders: Distribution by Type of RNAi Molecule
Figure 11.1 Clinical Trial Analysis: Methodology
Figure 11.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2014-2022
Figure 11.3 Clinical Trial Analysis: Distribution of Trials by Start Year and Type of Molecule, Pre-2014 – 2022
Figure 11.4 Clinical Trial Analysis: Cumulative Distribution of Enrolled Patient Population by Study Start Year, Pre-2014 - 2022
Figure 11.5 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 11.6 Clinical Trial Analysis: Distribution by Trial Recruitment Status and Phase of Development
Figure 11.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.8 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Trial Recruitment Status
Figure 11.9 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Trial Registration Year
Figure 11.10 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Phase of Development
Figure 11.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 11.12 Clinical Trial Analysis: Distribution by Therapeutic Area and Phase of Development
Figure 11.13 Clinical Trial Analysis: Geographical Distribution of Clinical Trials
Figure 11.14 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Recruitment Status
Figure 11.15 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Type of RNAi Molecule
Figure 11.16 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Type of RNAi Molecule
Figure 11.17 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Therapeutic Area
Figure 11.18 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Therapeutic Area
Figure 11.19 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Figure 11.20 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Recruitment Status
Figure 11.21 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Type of RNAi Molecule
Figure 11.22 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Type of RNAi Molecule
Figure 11.23 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Therapeutic Area
Figure 11.24 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Therapeutic Area
Figure 12.1 KOL Analysis: Distribution by Type of Organization
Figure 12.2 KOL Analysis: Distribution by Qualification
Figure 12.3 KOL Analysis: Distribution by Geographical Location
Figure 12.4 Most Prominent Organizations: Distribution by Number of KOLs
Figure 12.4 Scatter Plot: KOL Activeness v/s KOL Strength
Figure 12.5 Most Prominent KOLs: Distribution by KOL Strength
Figure 12.6 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 12.7 Linear Regression Analysis: Comparison of RA Score with Third-Party Score
Figure 12.8 Most Prominent KOLs: KOL Activeness v/s KOL Strength
Figure 13.1 Patent Analysis: Distribution by Type of Patent
Figure 13.2 Patent Analysis: Cumulative Distribution by Publication Year, 2016-2022
Figure 13.3 Patent Analysis: Distribution by Patent Type and Publication Year
Figure 13.4 Patent Analysis: Distribution by CPC Symbols
Figure 13.5 Patent Analysis: Distribution by Type of Applicant
Figure 13.6 Patent Analysis: Distribution by Geography
Figure 13.7 Patent Analysis: North American Scenario
Figure 13.8 Patent Analysis: European Scenario
Figure 13.9 Patent Analysis: Asia-Pacific Scenario
Figure 13.10 Patent Analysis: Emerging Focus Areas
Figure 13.11 Leading Players (Industry): Distribution by Number of Patents
Figure 13.12 Leading Players (Non-Industry): Distribution by Number of Patents
Figure 13.13 Patent Analysis: Benchmarking by Patent Characteristics
Figure 13.14 Patent Analysis (Leading Industry Players): Benchmarking by Patent Characteristics
Figure 13.15 Patent Analysis: Distribution by Patent Age, 2016-2022
Figure 13.16 Patent Analysis: Categorizations based on Weighted Valuation Scores
Figure 13.17 Patent Analysis: Patent Valuation
Figure 14.1 Publication Analysis: Cumulative Year-wise Trend, 2016-2021
Figure 14.2 Publication Analysis: Distribution by Type of Publication
Figure 14.3 Publication Analysis: Most Popular Keywords
Figure 14.4 Most Popular Journals: Distribution by Number of Publications
Figure 14.5 Most Popular Publishers: Distribution by Number of Publications
Figure 14.6 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 14.7 Key Funding Institutes: Distribution by Number of Publications
Figure 15.1 Partnerships: Cumulative Year-Wise Trend, 2014-2022
Figure 15.2 Partnerships: Distribution by Type of Partnership
Figure 15.3 Partnerships: Year-wise Trend by Type of Partnership
Figure 15.4 Partnerships: Distribution by Type of RNAi Molecule
Figure 15.5 Partnerships: Distribution by Scale of Partnership
Figure 15.6 Partnerships: Distribution by Therapeutic Area
Figure 15.7 Most Active Players: Distribution by Number of Partnerships
Figure 15.8 Partnerships: Local and International Agreements
Figure 15.9 Partnerships: Intercontinental and Intracontinental Distribution
Figure 16.1 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment, 2014-2021
Figure 16.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2014-2021
Figure 16.3 Funding and Investment Analysis: Cumulative Amount Invested, 2014-2021 (USD Million)
Figure 16.4 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested, 2014-2021
Figure 16.5 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2014-2021
Figure 16.6 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2014-2021 (USD Million)
Figure 16.7 Funding and Investments: Distribution of Number of Instances by Year and Type of Funding
Figure 16.8 Funding and Investments: Distribution by Amount Invested across Different Types of RNAi Therapeutics
Figure 16.9 Funding and Investment Analysis: Distribution by Geography
Figure 16.10 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 16.11 Most Active Players: Distribution by Number of Instances, 2014-2021
Figure 16.12 Most Active Players: Distribution by Amount Invested, 2014-2021 (USD Million)
Figure 16.13 Key Investors: Distribution by Number of Instances
Figure 16.14 Funding and Investment Summary, 2014-2021 (USD Million)
Figure 17.1 Successful Drug Launch Strategy: ROOTS Framework
Figure 17.2 Successful Drug Launch Strategy: Product Differentiation
Figure 17.3 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
Figure 17.4 Harvey Ball Analysis: Commercialization Strategies Adopted by RNAi-Based Therapy Developers
Figure 17.5 Approved RNAi Therapies: Snapshot of Promotional Activities on Product Websites
Figure 17.6 Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
Figure 18.1 Circulating miRNA Biomarkers: Key Criteria
Figure 18.2 Factors Determining Useful Cancer Screening
Figure 18.3 Conventional Methods for Cancer Diagnosis
Figure 19.1 RNAi Therapeutics: Types of Service Providers
Figure 19.2 RNAi Therapeutic CROs: Distribution by Year of Establishment
Figure 19.3 RNAi Therapeutics CROs: Distribution by Location of Headquarters
Figure 19.4 RNAi Therapeutics CROs: Distribution by Company Size
Figure 19.6 RNAi Therapeutics CMOs: Distribution by Year of Establishment
Figure 19.7 RNAi Therapeutics CMOs: Distribution by Location of Headquarters
Figure 19.8 RNAi Therapeutics CMOs: Distribution by Company Size
Figure 19.10 RNAi Therapeutic Consumable Providers: Distribution by Year of Establishment
Figure 19.11 RNAi Therapeutic Consumable Providers: Distribution by Location of Headquarters
Figure 19.12 RNAi Therapeutic Consumable Providers: Distribution by Company Size
Figure 20.1 Global Demand for RNAi Therapeutics, 2022-2035 (in terms of Target Patient Population)
Figure 20.2 Demand Analysis: Distribution by Type of Molecule, 2025, 2030 and 2035 (in terms of Target Patient Population)
Figure 20.3 Demand Analysis: Distribution by Therapeutic Area, 2025, 2030 and 2035 (in terms of Target Patient Population)
Figure 20.4 Demand Analysis: Distribution by Route of Administration, 2025, 2030 and 2035 (in terms of Target Patient Population)
Figure 20.5 Demand Analysis: Distribution by Key Players, 2025, 2030 and 2035 (in terms of Target Patient Population)
Figure 20.6 Demand Analysis: Distribution by Geography, 2025, 2030 and 2035 (in terms of Target Patient Population)
Figure 21.1 Overall RNAi Therapeutics Market, 2022-2035: Base Scenario (USD Billion)
Figure 21.2 RNAi Therapeutics Market: Distribution by Type of RNAi Molecule, 2025, 2030 and 2035 (USD Million)
Figure 21.3 RNAi Therapeutics Market: Distribution by Therapeutic Area, 2025, 2030 and 2035 (USD Billion)
Figure 21.4 RNAi Therapeutics Market: Distribution by Route of Administration, 2025, 2030 and 2035 (USD Million)
Figure 21.5 RNAi Therapeutics Market: Distribution by Share of Leading Players, 2025, 2030 and 2035 (USD Million)
Figure 21.6 RNAi Therapeutics Market: Distribution by Geography, 2025, 2030 and 2035
Figure 21.7 Onpattro Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 21.8 Givosiran Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 21.9 Inclisiran Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 21.10 Lumasiran Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 21.11 Fitusiran Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 21.12 Vutrisiran Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 21.13 SYL 1001 Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 21.14 Vigil-EWS Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 21.15 Nedosiran Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 22.1 RNAi Therapeutics: SWOT Analysis
Figure 22.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 24.1 Concluding Remarks: Market Overview
Figure 24.2 Concluding Remarks: Competitive Landscape
Figure 24.3 Concluding Remarks: Company Competitiveness Analysis
Figure 24.4 Concluding Remarks: Technology Platforms and Delivery Systems
Figure 24.5 Concluding Remarks: Technology Competitiveness Analysis
Figure 24.6 Concluding Remarks: Clinical Trial Analysis
Figure 24.7 Concluding Remarks: Key Opinion Leaders
Figure 24.8 Concluding Remarks: Patent Analysis
Figure 24.9 Concluding Remarks: Publication Analysis
Figure 24.10 Concluding Remarks: Recent Partnerships
Figure 24.11 Concluding Remarks: Funding and Investment Analysis
Figure 24.12 Concluding Remarks: Key Commercialization Strategies
Figure 24.13 Concluding Remarks: Demand Analysis
Figure 24.14 Concluding Remarks: Market Sizing and Opportunity Analysis (1/2)
Figure 24.15 Concluding Remarks: Market Sizing and Opportunity Analysis (2/2)

List Of Tables

Table 3.1 Merits and Demerits of RNAi Delivery Systems
Table 3.2 Comparison between siRNA, miRNA and shRNA
Table 4.1 RNAi Therapeutics: Marketed and Development Pipeline
Table 4.2 RNAi Therapeutics: Information on Special Drug Designation
Table 5.1 RNAi Therapeutics: List of Developers
Table 7.1 RNAi Therapeutics: List of Marketed and Approved Products
Table 7.2 Onpattro® (Patisiran): Drug Overview
Table 7.3 Onpattro® (Patisiran): Information on Completed and Active Clinical Trials
Table 7.4 Givlaari® (ALN-AS1): Drug Overview
Table 7.5 Givlaari®: Information on Completed and Active Clinical Trials
Table 7.6 Leqvio® (Inclisiran): Drug Overview
Table 7.7 Leqvio® (Inclisiran): Information on Completed and Active Clinical Trials
Table 7.8 Oxlumo® (Lumasiran): Drug Overview
Table 7.9 Oxlumo® (Lumasiran): Information on Completed and Active Clinical Trials
Table 7.10 Fitusiran (ALN-AT3): Drug Overview
Table 7.11 Fitusiran (ALN-AT3): Information on Completed and Active Clinical Trials
Table 7.12 Vutrisiran (ALN-TTRsc02): Drug Overview
Table 7.13 Vutrisiran (ALN-TTRsc02): Information on Completed and Active Clinical Trials
Table 7.14 SYL1001(Tivanisiran): Drug Overview
Table 7.15 SYL1001(Tivanisiran): Information on Completed and Active Clinical Trials
Table 7.16 Vigil-EWS: Drug Overview
Table 7.17 Vigil-EWS: Information on Completed and Active Clinical Trials
Table 7.18 Nedosiran: Drug Overview
Table 7.19 Nedosiran: Completed and Active Clinical Trials
Table 8.1 Self-deliverable RNA molecules
Table 8.2 List of RNAi Technology / Platforms
Table 8.3 List of RNAi Technology Developers
Table 8.4 ESC-GalNAc: Pipeline Molecules
Table 8.5 Protein Nanoparticle Delivery Technology: Pipeline Molecules
Table 8.6 TRiM: Pipeline Molecules
Table 8.7 GalXC: Pipeline Molecules
Table 8.8 Vigil: Pipeline Molecules
Table 8.9 mRNAi GOLD Platform: Pipeline Molecules
Table 11.1 Clinical Trial Analysis: Key Therapeutic Candidates
Table 11.2 Clinical Trial Analysis: Key Clinical Trials
Table 12.1 Key Opinion Leaders: List of Principal Investigators Involved in Clinical Trials
Table 13.1 Patent Analysis: CPC Code Definitions
Table 13.2 Patent Analysis: Most Popular CPC Codes
Table 13.3 Patent Analysis: List of Top CPC Codes
Table 13.4 Patent Analysis: Summary of Benchmarking Analysis
Table 13.5 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 14.1 RNAi Therapeutics: List of Publications
Table 15.1 RNAi Therapeutics: List of Partnerships, 2014-2022
Table 16.1 RNAi Therapeutics: List of Funding and Investments, 2014-2021
Table 16.2 Funding and Investment Analysis: Summary of Investments
Table 17.1 Onpattro®: Presentations in Conferences Before Product Approval
Table 17.2 Givlaari®: Presentations in Conferences Before Product Approval
Table 17.3 Oxlumo®: Presentations in Conferences Before Product Approval
Table 17.4 Onpattro®: Presentations in Conferences After Product Approval
Table 17.5 Leqvio®: Presentations in Conferences Before Product Approval
Table 17.6 Approved RNAi Therapies: Patient Support Services Available on Product Websites (Comparative Analysis)
Table 17.7 Leqvio®: Presentations in Conferences After Product Approval
Table 17.8 Approved RNAi Therapies: Patient Support Services Available on Product Websites (Comparative Analysis)
Table 18.1 Survival on Early Diagnosis of Cancer
Table 18.2 Cost of Biopsy for Different Cancer Indications (in USD)
Table 18.4 Breast Cancer: Reported miRNA Biomarkers
Table 18.5 Colorectal Cancer: Reported miRNA Biomarkers
Table 18.6 Gastric Cancer: Reported miRNA Biomarkers
Table 18.7 AML: Reported miRNA Biomarkers
Table 18.8 de novo DLBCL: Reported miRNA Biomarkers
Table 18.9 Lung Cancer: Reported miRNA Biomarkers
Table 18.10 Prostate Cancer: Reported miRNA Biomarkers
Table 18.11 Coronary Artery Disease: Reported miRNA Biomarkers
Table 18.12 Myocardial Infarction: Reported miRNA Biomarkers
Table 18.13 miRNA Diagnostic Tests: Pipeline
Table 19.1 RNAi Therapeutics: List of CROs
Table 19.2 RNAi Therapeutics: List of CMOs
Table 19.3 RNAi Therapeutics: List of Consumables Providers and Other Service Providers
Table 21.1 RNAi Therapeutics: Expected Launch Year of Advanced Stage Drug Candidates
Table 21.2 Onpattro®: Target Patient Population
Table 21.3 Onpattro®: Net Present Value (USD Million)
Table 21.4 Onpattro®: Value Creation Analysis (USD Million)
Table 21.5 Givlaari®: Target Patient Population
Table 21.6 Givlaari®: Net Present Value (USD Million)
Table 21.7 Givlaari®: Value Creation Analysis (USD Million)
Table 21.8 Leqvio®: Target Patient Population
Table 21.9 Leqvio®: Net Present Value (USD Million)
Table 21.10 Leqvio®: Value Creation Analysis (USD Million)
Table 21.11 Oxlumo®: Target Patient Population
Table 21.12 Oxlumo®: Net Present Value (USD Million)
Table 21.13 Oxlumo®: Value Creation Analysis (USD Million)
Table 21.14 Fitusiran: Target Patient Population
Table 21.15 Fitusiran: Net Present Value (USD Million)
Table 21.16 Fitusiran: Value Creation Analysis (USD Million)
Table 21.17 Vutrisiran: Target Patient Population
Table 21.18 Vutrisiran: Net Present Value (USD Million)
Table 21.19 Vutrisiran: Value Creation Analysis (USD Million)
Table 21.20 SYL 1001: Target Patient Population
Table 21.21 SYL 1001: Net Present Value (USD Million)
Table 21.22 SYL 1001: Value Creation Analysis (USD Million)
Table 21.23 Vigil-EWS: Target Patient Population
Table 21.24 Vigil-EWS: Net Present Value (USD Million)
Table 21.25 Vigil-EWS: Value Creation Analysis (USD Million)
Table 21.26 Nedosiran: Target Patient Population
Table 21.27 Nedosiran: Net Present Value (USD Million)
Table 21.28 Nedosiran: Value Creation Analysis (USD Million)
Table 22.1 RNAi Therapeutics: SWOT Analysis
Table 22.2 Comparison of SWOT Factors: Harvey Ball Analysis
Table 24.1 Concluding Remarks: Market Overview
Table 24.2 Concluding Remarks: Competitive Landscape
Table 24.3 Concluding Remarks: Company Competitiveness Analysis
Table 24.4 Concluding Remarks: Technology Competitiveness Analysis
Table 24.5 Concluding Remarks: Clinical Trial Analysis
Table 24.6 Concluding Remarks: Key Opinion Leaders
Table 24.7 Concluding Remarks: Patent Analysis
Table 24.8 Concluding Remarks: Publication Analysis
Table 24.9 Concluding Remarks: Recent Partnerships
Table 24.10 Concluding Remarks: Funding and Investment Analysis
Table 24.11 Concluding Remarks: Demand Analysis
Table 24.12 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 25.1 RNAi Therapeutics: Distribution by Type of RNAi Molecule
Table 25.2 RNAi Therapeutics: Distribution by Phase of Development
Table 25.3 RNAi Therapeutics: Distribution by Type of RNAi Molecule and Phase of Development
Table 25.4 RNAi Therapeutics: Distribution by Target Gene
Table 25.5 RNAi Therapeutics: Distribution by Therapeutic Area
Table 25.6 RNAi Therapeutics: Distribution by Route of Administration
Table 25.7 RNAi Therapeutics: Distribution by Special Drug Designation
Table 25.8 RNAi Therapeutics: Distribution by Special Drug Designation and Therapeutic Area
Table 25.9 RNAi Therapeutics: Key Players
Table 25.10 RNAi Therapeutics Developers: Distribution by Year of Establishment
Table 25.11 RNAi Therapeutics Developers: Distribution by Company Size
Table 25.12 RNAi Therapeutics Developers: Distribution by Location of Headquarters (Continent-wise)
Table 25.13 RNAi Therapeutics Developers: Distribution by Location of Headquarters (Country-wise)
Table 25.14 RNAi Therapeutics Developers: Key Players
Table 25.15 RNAi Technology Platforms: Distribution by Purpose of Technology
Table 25.16 RNAi Technology Platforms: Distribution by Type of Molecule(s) Delivered
Table 25.17 RNAi Technology Platforms: Distribution by Type of Cell/ Tissue Targeted
Table 25.18 RNAi Technology Developers: Distribution by Year of Establishment
Table 25.19 RNAi Technology Developers: Distribution by Company Size
Table 25.20 RNAi Technology Developers: Distribution by Location of Headquarters (Continent-wise)
Table 25.21 RNAi Technology Developers: Distribution by Location of Headquarters (Country-wise)
Table 25.22 RNAi Therapeutics for Oncological Disorders: Distribution by Target Indication and Phase of Development
Table 25.23 RNAi Therapeutics for Oncological Disorders: Distribution by Type of RNAi Molecule
Table 25.24 RNAi Therapeutics for Infectious Diseases: Distribution by Target Indication and Phase of Development
Table 25.25 RNAi Therapeutics for Infectious Diseases: Distribution by Type of RNAi Molecule
Table 25.26 RNAi Therapeutics for Metabolic Disorders: Distribution by Target Indication and Phase of Development
Table 25.27 RNAi Therapeutics for Metabolic Disorders: Distribution by Type of RNAi Molecule
Table 25.28 RNAi Therapeutics for Ophthalmic Diseases: Distribution by Target Indication and Phase of Development
Table 25.29 RNAi Therapeutics for Ophthalmic Diseases: Distribution by Type of RNAi Molecule
Table 25.30 RNAi Therapeutics for Genetic Disorders: Distribution by Target Indication and Phase of Development
Table 25.31 RNAi Therapeutics for Genetic Disorders: Distribution by Type of RNAi Molecule
Table 25.32 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2014-2022
Table 25.33 Clinical Trial Analysis: Distribution of Trials by Start Year and Type of Molecule, Pre-2014 – 2022
Table 25.34 Cumulative Distribution of Enrolled Patient Population by Study Start Year, Pre-2014 - 2022
Table 25.35 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.36 Clinical Trial Analysis: Distribution by Trial Recruitment Status and Phase of Development
Table 25.37 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.38 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Trial Recruitment Status
Table 25.39 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Trial Registration Year
Table 25.40 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Phase of Development
Table 25.41 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 25.42 Clinical Trial Analysis: Distribution by Therapeutic Area and Phase of Development
Table 25.43 Clinical Trial Analysis: Geographical Distribution of Clinical Trials
Table 25.44 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Recruitment Status
Table 25.45 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Type of RNAi Molecule
Table 25.46 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Type of RNAi Molecule
Table 25.47 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Therapeutic Area
Table 25.48 Geographical Analysis by Number of Clinical Trials, Therapeutic Area and Trial Phase
Table 25.49 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Table 25.50 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Recruitment Status
Table 25.51 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Type of RNAi Molecule
Table 25.52 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Type of RNAi Molecule
Table 25.53 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Therapeutic Area
Table 25.54 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Therapeutic Area
Table 25.55 Key Opinion Leaders: Distribution by Type of Organization
Table 25.56 KOL Analysis: Distribution by Qualification
Table 25.57 KOL Analysis: Distribution by Geographical Location
Table 25.58 Most Prominent Organizations: Distribution by Number of KOLs
Table 25.59 Most Prominent KOLs: Distribution by KOL Strength
Table 25.60 Patent Analysis: Distribution by Type of Patent
Table 25.61 Patent Analysis: Cumulative Distribution by Publication Year, 2016-2022
Table 25.62 Patent Analysis: Distribution by Patent Type and Publication Year
Table 25.63 Patent Analysis: Distribution by Type of Applicant
Table 25.64 Patent Analysis: Distribution by Geography
Table 25.65 Patent Analysis: North American Scenario
Table 25.66 Patent Analysis: European Scenario
Table 25.67 Patent Analysis: Asia-Pacific Scenario
Table 25.68 Leading Players (Industry): Distribution by Number of Patents
Table 25.69 Leading Players (Non-Industry): Distribution by Number of Patents
Table 25.70 Patent Analysis: Distribution by Patent Age, 2016-2022
Table 25.71 Publication Analysis: Cumulative Year-wise Trend, 2016-2022
Table 25.72 Publication Analysis: Distribution by Type of Publication
Table 25.73 Publication Analysis: Most Popular Keywords
Table 25.74 Top Journals: Distribution by Number of Publications
Table 25.75 Top Publishers: Distribution by Number of Publications
Table 25.76 Key Copyright Holders: Distribution by Number of Publications
Table 25.77 Key Funding Institutes: Distribution by Number of Publications
Table 25.78 Partnerships: Cumulative Year-Wise Trend, 2014-2022
Table 25.79 Partnerships: Distribution by Type of Partnership
Table 25.80 Partnerships: Year-wise Trend by Type of Partnership
Table 25.81 Partnerships: Distribution by Type of RNAi Molecule
Table 25.82 Partnerships: Distribution by Scale of Partnership
Table 25.83 Partnerships: Distribution by Therapeutic Area
Table 25.84 Most Active Players: Distribution by Number of Partnerships
Table 25.85 Partnerships: Local and International Agreements
Table 25.86 Partnerships: Intercontinental and Intracontinental Distribution
Table 25.87 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment, 2014-2021
Table 25.88 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2014-2021
Table 25.89 Funding and Investment Analysis: Cumulative Amount Invested, 2014-2021 (USD Million)
Table 25.90 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2014-2021
Table 25.91 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2014-2021 (USD Million)
Table 25.92 Funding and Investments: Distribution of Number of Instances by Year and Type of Funding
Table 25.93 Funding and Investments: Distribution of Amount Invested across Different Types of RNAi Therapeutics
Table 25.94 Funding and Investment Analysis: Distribution by Geography
Table 25.95 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 25.96 Most Active Players: Distribution by Number of Instances, 2014-2021
Table 25.97 Most Active Players: Distribution by Amount Invested, 2014-2021 (USD Million)
Table 25.98 Key Investors: Distribution by Number of Instances
Table 25.99 RNAi Therapeutics: Types of Service Providers
Table 25.100 RNAi Therapeutic CROs: Distribution by Year of Establishment
Table 25.101 RNAi Therapeutics CROs: Distribution by Location of Headquarters
Table 25.102 RNAi Therapeutics CROs: Distribution by Company Size
Table 25.103 RNAi Therapeutics CROs: Distribution by Type of RNAi Molecule
Table 25.104 RNAi Therapeutics CMOs: Distribution by Year of Establishment
Table 25.105 RNAi Therapeutics CMOs: Distribution by Location of Headquarters
Table 25.106 RNAi Therapeutics CMOs: Distribution by Company Size
Table 25.107 RNAi Therapeutic Consumable Providers: Distribution by Year of Establishment
Table 25.108 RNAi Therapeutic Consumable Providers: Distribution by Location of Headquarters
Table 25.109 RNAi Therapeutic Consumable Providers: Distribution by Company Size
Table 25.110 RNAi Therapeutic Consumable Providers: Distribution by Type of RNAi Molecule
Table 25.111 Global Demand for RNAi Therapeutics, 2022-2035 (in terms of Target Patient Population)
Table 25.112 Demand Analysis: Distribution by Type of Molecule, 2025, 2030 and 2035 (in terms of Target Patient Population)
Table 25.113 Demand Analysis: Distribution by Therapeutic Area, 2025, 2030 and 2035 (in terms of Target Patient Population)
Table 25.114 Demand Analysis: Distribution by Route of Administration, 2025, 2030 and 2035 (in terms of Target Patient Population)
Table 25.115 Demand Analysis: Distribution by Key Players, 2025, 2030 and 2035 (in terms of Target Patient Population)
Table 25.116 Demand Analysis: Distribution by Geography, 2025, 2030 and 2035 (in terms of Target Patient Population)
Table 25.117 Overall RNAi Therapeutics Market, 2022-2035 (USD Billion)
Table 25.118 RNAi Therapeutics Market: Distribution by Type of RNAi Molecule, 2025, 2030 and 2035 (USD Million)
Table 25.119 RNAi Therapeutics Market: Distribution by Therapeutic Area, 2025, 2030 and 2035 (USD Billion)
Table 25.120 RNAi Therapeutics Market: Distribution by Route of Administration, 2025, 2030 and 2035 (USD Million)
Table 25.121 RNAi Therapeutics Market: Distribution by Share of Leading Players, 2025, 2030 and 2035 (USD Million)
Table 25.122 RNAi Therapeutics Market: Distribution by Geography, 2025, 2030 and 2035 (USD Billion)
Table 25.123 Onpattro Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.124 Givosiran Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.125 Inclisiran Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.126 Lumasiran Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.127 Fitusiran Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.128 Vutrisiran Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.129 SYL 1001 Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.130 Vigil-EWS Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.131 Nedosiran Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report

1. 1Globe Health Institute
2. 20Med Therapeutics
3. Adhera Therapeutics
4. Advirna
5. Ajinomoto Bio-Pharma Services
6. Alexion Pharmaceuticals
7. Allele Biotechnology
8. Alnylam Pharmaceuticals
9. Altogen Labs
10. AM Chemicals
11. Amgen
12. AMSBIO
13. Anjarium Biosciences
14. Applied Biological Materials (abm) 
15. Arbutus Biopharma
16. Arcturus Therapeutics
17. ARIZ Precision Medicine
18. Aro Biotherapeutics
19. Arrowhead Pharmaceuticals
20. Ascletis Pharma
21. AstraZeneca
22. Atlanta Therapeutics
23. AUM LifeTech
24. Avidity Biosciences
25. Benitec Biopharma
26. BianoScience
27. Bioasis Technologies
28. BioAxone BioSciences
29. Biomics Biopharma
30. Bioneer
31. Biosettia 
32. BioSpring
33. Bio-Synthesis
34. bluebird bio
35. Boehringer Ingelheim
36. Boston Children’s Hospital
37. BR Biochem Life Sciences
38. Bristol-Myers Squibb
39. Calimmune (Acquired by CSL Behring)
40. Cell Signaling Technology
41. Cellecta
42. Celsion
43. Certara
44. Charles River Laboratories
45. CMIC Group
46. CordenPharma
47. Creative Animodel
48. Creative Biogene
49. Creative Biolabs
50. CUSABIO TECHNOLOGY
51. Dharmacon (Acquired by Horizon Discovery)
52. Dicerna Pharmaceuticals
53. Eli Lilly
54. Entos Pharmaceuticals
55. Eurofins Genomics
56. Eurogentec
57. Evotec
58. Exiqon
59. GCC Biotech
60. GeneCopoeia
61. GeneCust
62. GeneDesign (Acquired by Ajinomoto Bio-Pharma Services)
63. Genel
64. GenePharma
65. Genevant Sciences
66. GlaxoSmithKline
67. Gradalis
68. Halo-Bio RNAi Therapeutics
69. Hansoh Pharma
70. HISTALIM
71. Horizon Therapeutics
72. Hugel
73. IIDong Pharmaceutical
74. Integrated DNA Technologies
75. InteRNA Technologies
76. iTherapeutics
77. Janssen Pharmaceuticals
78. Kanglin Biotec
79. LC Sciences
80. Lemonex
81. LGC, Biosearch Technologies
82. Mallinckrodt Pharmaceuticals
83. MD Anderson Cancer Center
84. Microsynth
85. miReven
86. Mirimus
87. Mirus Bio
88. MultiplexDX
89. NanoDe Therapeutics
90. NantWorks
91. National Cancer Institute (NCI)
92. Netherlands Organisation for Health Research and Development (ZonMw)
93. Nitto BioPharma
94. Nitto Denko
95. Nitto Denko Avecia
96. Novartis (The Medicines Company)
97. Novo Nordisk
98. Nucleome Informatics
99. Oligoengine
100. OliX Pharmaceuticals
101. OriGene Technologies
102. OZ Biosciences
103. PCI Biotech
104. Phalanx Biotech
105. Pharmaron
106. Phio Pharmaceuticals (previously Rxi Pharmaceuticals)
107. Phyzat
108. Polyplus-transfection
109. Promega
110. QIAGEN
111. Quark Pharmaceuticals
112. Radboud University
113. Regen BioPharma
114. Regeneron
115. Regulus Therapeutics
116. RiboBio
117. Roche
118. Sanofi Genzyme
119. Santa Cruz Biotechnology 
120. Shanghai Biotechnology
121. Shanghai Public Health Clinical Center
122. Sigma-Aldrich
123. Silence Therapeutics
124. Silenseed 
125. SIRION Biotech
126. Sirnaomics
127. siTools Biotech
128. Soluventis 
129. SomaGenics
130. Sumitomo Chemical
131. Suzhou Ribo Life Science
132. Sylentis
133. Syngene
134. Takara Bio
135. Takeda Pharmaceuticals
136. tebu-bio
137. Théa Open Innovation
138. Thermo Fisher Scientific 
139. Transgene Biotek
140. Translate Bio (Acquired by Sanofi)
141. Transomic Technologies
142. TriPhos Therapeutics
143. UCSF Diabetes Research Center (DRC) Lentiviral RNAi Core
144. University of Virginia School of Medicine
145. Vector Biolabs 
146. Vir Biotechnology 
147. Viridian Therapeutics
148. ViThera
149. Westen Biotechnology

Source: pubmed.ncbi.nlm.nih.gov/15580776/